Scaling the science into any kind of business “is just really tough, but scaling a biotechnology company in South Africa is ...

Anthropic plans to expand its growing presence in life sciences by investing further in knowledge, talent, partnerships, and ...

The collective activity of all six genes, which the researchers called the PHFScore, divided patients into groups with ...

Closing the execution gap is one of the greatest opportunities biopharma has today to enhance resilience and unlock the full ...

The University of Washington School of Medicine Institute for Protein Design (IPD) has partnered with Nvidia to develop an ...

IMU Biosciences and UK Biobank will profile 80,000 blood samples using technologies from Waters and Ultima Genomics.

A small-molecule therapy, VG-3927, targeting microglial TREM2 signaling showed neuroprotective effects in preclinical studies ...

The companies plan to first optimize Takara's SMART-seq RNA-seq library prep workflows on SPT Labtech's firefly liquid ...

The list of tools includes SpliceA12, a new iteration of a genomic AI model designed to identify disease-relevant splice ...

Limiting expansion steps to three days could increase the proportion of naive T cells in, and speed up the production of, CAR T-cell therapies.

In this GEN webinar, Bernd Bodenmiller, PhD (University of Zürich), illustrates this integrated approach through two recent examples.

Strategic automation and flexible bioprocessing could help cell and gene therapies scale across diverse APAC markets.